Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X:
“What a terrific 2 weeks for breast oncology:
- Dato-DXd approved for HR+/HER2- mBC
- T-DXd approval expanded to HER2-ultralow disease
- inavolisib triplet announced to prolong OS
And I can bet that some more practice changing data is being submitted to ASCO25 before midnight.”